News headlines about Ariad Pharmaceuticals (NASDAQ:ARIA) have trended somewhat negative recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ariad Pharmaceuticals earned a daily sentiment score of -0.05 on Accern’s scale. Accern also gave news coverage about the pharmaceutical company an impact score of 45.6894302530979 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern’s rankings:

Ariad Pharmaceuticals (NASDAQ:ARIA) remained flat at $$23.99 during trading hours on Friday. The company has a debt-to-equity ratio of -11.28, a quick ratio of 3.15 and a current ratio of 3.17.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at

Ariad Pharmaceuticals Company Profile

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Insider Buying and Selling by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)

Receive News & Ratings for Ariad Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals and related companies with's FREE daily email newsletter.